3 results
Approved WMOWill not start
The primary objective of this study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.Secondary objectives include evaluation of the safety and effect of ambrisentan on development of…
Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease
Primary objective: determining the effect of the ketohexokinase inhibitor, PF-06835919, on hepatic insulin sensitivity in individuals with non-alcoholic fatty liver disease.Secondary objective: determining the effect of the ketohexokinase inhibitor…
Approved WMORecruiting
To study the effects of PF-06835919 on fructose tolerance and intrahepatic lipid content in patients with HFI.